Clinical trial · Interventional
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
A Phase I and a Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) With or Without MEDI-522 (NSC-719850)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This phase I/randomized phase II trial is studying the side effects and best dose of bevacizumab and to see how well it works when given together with or without MEDI-522 in treating patients with unresectable or metastatic kidney cancer. Monoclonal antibodies, such as bevacizumab and MEDI-522, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab and MEDI-522 may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether bevacizumab is more effective when given together with or without MEDI-522 in treating kidney cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
| Stage III Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
| Stage IV Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab | Biological | Bevacizumab | ALIAS |
| etaracizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Phase II Arm I
- description
- Patients receive bevacizumab (10mg/kg) IV over 30-90 minutes on days 1 and 15.
- interventionNames
- Biological: bevacizumab
- type
- ACTIVE_COMPARATOR
- label
- Phase II Arm II
- description
- Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
- interventionNames
- Drug: etaracizumab
- Biological: bevacizumab
Primary outcomes (5)
- measure
- Maximum Tolerated Dose of Bevacizumab , Based on Incidence of Dose-limiting Toxicity (DLT) Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Criteria: * Histologically or cytologically confirmed renal cell carcinoma * Metastatic or unresectable disease * Must have received prior sunitinib malate or sorafenib tosylate for metastatic or unresectable disease * Measurable disease * No soft tissue disease that has been irradiated within the past 2 months * More than 6 months since prior and no concurrent treated or untreated brain metastases * Stable, treated brain metastases allowed provided they remained stable for more than 6 months * Patients with clinical evidence of brain metastases must have a negative brain CT or MRI scan for metastatic disease * Zubrod performance status 0-1 * Urine protein:creatinine ratio =\< 0.5 OR urine protein \< 1,000 mg by 24-hour collection * Not be pregnant or nursing * Fertile patients must use effective contraception during and for at least 6 months after completion of study therapy * No serious or non-healing wound, ulcer, or bone fracture * No clinically relevant bleeding diathesis or coagulopathy * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days * No significant traumatic injury within the past 28 days * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * No other prior malignancy, except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years * No New York Heart Association class II-IV congestive heart failure * No unstable symptomatic arrhythmia requiring medication * Chronic, controlled arrhythmias (e.g., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed * None of the following cardiovascular conditions within the past 6 months: Arterial thrombosis, Unstable angina, Myocardial infarction, Cerebrovascular accident * Must have controlled blood pressure, defined as systolic blood pressure (BP) =\< 160 mm Hg and/or diastolic BP =\< 90 mm Hg * More than 7 days since prior core biopsy * At least 14 days since completion of prior therapy and recovered * At least 28 days since prior radiotherapy and recovered * No prior radiotherapy to \>= 25% of bone marrow * No more than two prior systemic regimens for renal cell carcinoma (including adjuvant treatment) * No prior bevacizumab or humanized monoclonal antibody MEDI-522 * No major surgical procedure or open biopsy within the past 28 days * No concurrent need for a major surgical procedure * Concurrent full-dose anticoagulation with warfarin allowed provided INR is between 2-3 * Concurrent low molecular weight heparin allowed * No clinically significant vascular disease (e.g., aortic aneurysm or history of aortic dissection)
References
Publications (0)
Data not yet available